CGEM Cullinan Therapeutics, Inc. Common Stock
XNAS
14.54
Delayed
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Expected move IV rank history Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
CGEM
$14.54
—
Key stats
$14.54
Pre-market
$14.60
+0.41%
- 52-Week Range
- $6.73 – $23.19
- YTD
- +43.68%
- IV Rank (30D)
- 31.24
- Straddle Price
- $4.55
- P/C Vol Ratio
- 14.60
- Market Cap
- $0.9B
- Open
- $14.71
- Day Range
- $14.39 – $14.87
- Volume
- 438,575
- Prev Close
- $14.37
Fair Value
MODEL: LONG
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 4.96% |
| Beta vs SPY | 0.89 |
| Cost of Equity (CAPM) | 9.40% (VRP-adj) |
| WACC | 9.55% |
| Volatility Risk Premium | +60.7pp (IV − HV30) |
| Effective Tax Rate | 21.0% |
| Rev. Growth (YoY, DCF input) | +3.0% |
| DCF Horizon | 5 years explicit + fade |
| Forward Tilt (NTM/TTM) | ×1.03 (applied to P/E, EV/EBITDA, P/S) |
| Free Cash Flow (TTM) | $-0.2B |
| Return on Equity (TTM) | -55.6% |
| Book / Price | 36.9% — banking bias active (P/B is primary) |
| Debt / Equity | 0.00 |
| Quality Score | 1/6 — cyclical/struggling (5y DCF) |
| SMA 50 | $18.39 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $14.83 |
| Bollinger Width / SMA20 | 148.1% (drives anchor stability) |
| Net Debt | $-0.1B |
| Market Cap | $1B |
Peers used for multiples: AMGN, BIIB, EXEL, GILD, HALO, MRNA, NBIX, RGEN, RVMD, TECH
(SIC-code peers; ETF co-membership was sector-incoherent)
60-Day Conviction
70%
20-Day Fair Value
≈ by Nov 25, 2026
$14.72
α +1.2%
rank 96%
conviction
67%
40-Day Fair Value
≈ by Dec 24, 2026
$14.88
α +2.3%
rank 97%
conviction
74%
60-Day Fair Value
≈ by Jan 22, 2027
$14.88
α +2.4%
rank 94%
conviction
70%
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | n/a | 0% | |
| DDM (Gordon) | n/a | 0% | |
| Peer P/E | n/a | 0% | median 34.5× · 7 peers |
| Peer EV/EBITDA | n/a | 0% | median 18.3× · 8 peers |
| Peer P/B | $54.92 | 28% | median 10.2× · 10 peers |
| Peer P/S | n/a | 0% | median 6.6× · 9 peers |
| Market Anchor (SMA50) | $18.39 | 0% | stability 0% (BB-width) |
| Options Expected (B-L 30d) | $13.87 | 72% | 23 strikes · skew +0.24 |
As of 2026-10-27 · updated
Related
About
- Industry (SIC)
- BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) (2836) · industry map
- Exchange
- XNAS
- Market Cap
- $0.9B
- Employees
- 109
- List Date
- 2021-01-08
- CIK
- 0001789972
- Next Earnings
- 2026-11-05 (After-Close)
- EPS Forecast
- ($0.79) (6 est.)
- Headquarters
- Cambridge, MA
- Homepage
- https://www.cullinantherapeutics.com
Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, be…
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '21 | '22 | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|---|---|
| Jan | 27.08% | -18.25% | 8.99% | 42.97% | -14.77% | 18.18% | 10.70% |
| Feb | 19.69% | 2.65% | -2.50% | 5.48% | -15.61% | 21.95% | 5.28% |
| Mar | -13.89% | -25.16% | -9.71% | -7.94% | -5.37% | -11.13% | -12.20% |
| Apr | -21.31% | -10.74% | -7.33% | 53.03% | 10.40% | -6.38% | 2.95% |
| May | -13.20% | 1.52% | -0.10% | -16.37% | 1.47% | 22.41% | -0.71% |
| Jun | -11.51% | 13.05% | 5.91% | -22.63% | -13.94% | 12.34% | -2.80% |
| Jul | -14.76% | 4.49% | -1.03% | 15.66% | 1.70% | -5.12% | 0.16% |
| Aug | 16.80% | 1.35% | -0.29% | 4.48% | -1.69% | 35.82% | 9.41% |
| Sep | -21.66% | -1.54% | -16.59% | -9.56% | -20.83% | -29.55% | -16.62% |
| Oct | -10.22% | 2.42% | 11.34% | -7.22% | 44.33% | 0.07%* | 6.79% |
| Nov | -18.88% | -6.26% | -11.75% | -14.77% | 45.58% | -- | -1.22% |
| Dec | -6.82% | -13.95% | 17.67% | -7.52% | -3.72% | -- | -2.87% |
| Total | -58.10% | -44.58% | -10.47% | 9.87% | 5.07% | 49.80% | -8.07% |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $14.83
SMA 50: $18.39
SMA 200: $15.72
Current: $14.54
EMA 12: $14.69
EMA 26: $15.70
MACD: -1.0149 | Signal: 0.1999
BEARISH
ADX (14): 31.50
TREND
+DI: 18.46
−DI: 32.54
Momentum Oscillators
RSI (14): 41.06
NEUTRAL
Stoch %K: 41.34
Stoch %D: 41.28
Williams %R: -52.03
Volume & Volatility
BB Upper: $16.46
BB Lower: $13.20
NEUTRAL
OBV: 16,829,740
Vol SMA 20: 876,213
Vol ROC: 17.71%
ATR: $0.99
True Range: $0.50
HV 20: 67.9%
HV 30: 95.6%
HV 60: 77.0%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-10-28T00:00:00 – 2026-10-26T00:00:00
AI Analysis
LLM Stock Analysis Report
Executive Summary
BULLISH (confidence level: 8/10)
Key drivers:
- Strong technical momentum, with MACD signal line crossover indicating bullish momentum
- Positive recent news headlines highlighting clinical trial progress for CLN-978
- High volatility, which could lead to potential trading opportunities
Primary risks:
- Overbought RSI and Bollinger Bands position, suggesting potential near-term correction
- High beta (1.34) indicates higher volatility relative to the market
Investment thesis: CGEM's recent clinical trial progress and strong technical momentum make it an attractive buy opportunity for those willing to take on moderate risk.
Recent news sentiment impact: The positive recent news headlines have boosted investor confidence, contributing to the stock's bullish momentum.
Technical Analysis
Trend Direction:
- Short-term (1-4 weeks): Bullish
- Medium-term (1-3 months): Bullish
- Long-term (3-12 months): Neutral
Support/Resistance Levels:
- Upper Bollinger Band: $19.94
- Middle Bollinger Band: $17.88
- Lower Bollinger Band: $15.83
Momentum Signals:
- RSI interpretation: Overbought (>70) - potential sell signal, but MACD signal line crossover suggests continued bullish momentum.
- MACD signal (bullish/bearish crossover): Bullish
- Bollinger Bands position: Overbought
Volume Analysis:
- Volume SMA 20: 580753.10
- On-Balance Volume (OBV): 25932435.15
- Volume Rate of Change: -15.09% - suggests moderate institutional interest and potential selling pressure.
News & Sentiment Analysis
Recent Headlines Summary: The recent news headlines highlight the clinical trial progress for CLN-978, a CD19xCD3 T Cell Engager, in treatment-refractory rheumatoid arthritis and systemic lupus erythematosus. The positive sentiment suggests that investors are optimistic about the company's future prospects.
Sentiment Assessment: POSITIVE
Catalyst Identification: Upcoming clinical trial results for CLN-978 could be a catalyst for further price movement.
Market Narrative: The recent news headlines align with the technical signals, suggesting a bullish narrative.
Risk & Volatility Assessment
Beta Interpretation: High risk (beta 1.34) relative to the market, indicating higher volatility and potential price swings.
Volatility Regime: Current high volatility regime is consistent with the stock's beta value.
Options Market Signals:
- IV rank: Low (7.0%)
- Put/call ratio: Bearish sentiment (5.00)
- Open interest: 40 calls vs 121 puts - suggests moderate institutional selling pressure
Downside Protection: Support levels: Middle Bollinger Band ($17.88) and Lower Bollinger Band ($15.83)
Market Context & Positioning
Sector Performance: CGEM's sector (Biotechnology) is performing relatively well, with a higher beta value indicating increased volatility.
Institutional Activity: Moderate institutional interest and selling pressure are indicated by the volume analysis and options market signals.
Correlation Analysis: CGEM's correlation with the SPY index is 0.21, suggesting moderate diversification benefits.
Relative Valuation: CGEM's relative valuation within its trading range is neutral to slightly undervalued.
Key Levels & Action Items
Critical Price Levels:
- Support: Middle Bollinger Band ($17.88)
- Resistance: Upper Bollinger Band ($19.94)
Breakout/Breakdown Levels: Potential breakout above $20.00 or breakdown below $17.50
Time-Sensitive Catalysts: Upcoming clinical trial results for CLN-978 could be a catalyst for further price movement.
Risk Management: Stop-loss levels at $18.50 and position sizing considerations based on the stock's beta value and volatility regime.
**Please note that this analysis is purely hypothetical, and actual investment decisions should be made after consulting with a financial advisor and conducting thorough research.
Generated
News
All CGEM news →
Earnings History
15 of 15 under expected move
Avg Expected Move
23.84%
Avg Actual Move
3.58%
| Earnings Date | Timing | Expected Move | Actual Move | Ratio | Outcome |
|---|---|---|---|---|---|
| 2022-05-12 | After-Close | 20.33% | 18.00% | 0.89x | Within |
| 2023-05-11 | After-Close | 15.18% | 1.46% | 0.10x | Within |
| 2023-11-08 | After-Close | 12.58% | 3.52% | 0.28x | Within |
| 2024-01-08 | After-Close | 14.13% | 0.92% | 0.07x | Within |
| 2024-03-14 | After-Close | 17.50% | 5.80% | 0.33x | Within |
| 2024-08-08 | After-Close | 25.79% | 2.38% | 0.09x | Within |
| 2024-11-07 | After-Close | 31.93% | 2.82% | 0.09x | Within |
| 2025-02-27 | After-Close | 28.46% | 1.39% | 0.05x | Within |
| 2025-05-08 | After-Close | 12.55% | 2.96% | 0.24x | Within |
| 2025-08-07 | After-Close | 41.61% | 3.77% | 0.09x | Within |
| 2025-11-06 | After-Close | 35.37% | 2.18% | 0.06x | Within |
| 2026-01-08 | After-Close | 9.20% | 2.15% | 0.23x | Within |
| 2026-03-10 | After-Close | 37.39% | 4.02% | 0.11x | Within |
| 2026-05-07 | After-Close | 33.29% | 1.15% | 0.03x | Within |
| 2026-08-06 | After-Close | 22.28% | 1.23% | 0.06x | Within |
Earnings calendar: this week’s reports with expected vs actual moves →
CGEM Options Activity & IV Rank
CGEM IV rank history, 52-week IV rank and IV percentile →
Volatility Metrics
Current IV: 106.9%
7-DTE IV: —
Expected Move: $4.55
7-DTE Move: $4.55
Days to Exp: 25 (2026-11-20)
Options Flow
Call Volume: 109
Put Volume: 1,591
P/C Volume: 14.596
BEARISH
Call OI: 168
Put OI: 2,209
P/C OI: 13.149
Total OI: 2,377
ATM Options Pricing
ATM Call: $2.95
ATM Put: $1.60
Call %: 20.3%
Put %: 11.0%
Chain Summary
Chain Volume: 9,476
Chain OI: 14,686
Last Updated: 10/26/2026
Spread Scanner GPU
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score (GPU scanner)
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Dealer Positioning
LOW γ vs HISTORY
Estimated net dealer gamma is at the 7th percentile of this name's own daily history, near the low end of its range. This describes current positioning; it is not a forecast or a trading signal.
Gamma percentile
7%
vs own history
GEX tilt
-0.81
OI-weighted, today
Vanna tilt
-0.61
δ-sensitivity to IV
Charm tilt
+0.64
δ-decay vs time
Vanna tilt -0.61: the estimated dealer exposure leans negative, so the modeled hedge would shift noticeably if implied volatility changed.
Charm tilt +0.64: the estimated dealer exposure leans positive, so the modeled hedge would shift noticeably as time passes and options approach expiry.
? What is this?
· 14 ATM contracts, 3k total OI
Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.
Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.
Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.
This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
as of Oct 26 · No data
30 DTE / 10d
—
—
pts
EXTREME
as of Oct 26 · ATM 147.6% / Wing —
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Enter a ticker to render the implied volatility surface.
Volatility Smile
Enter a ticker to render the implied volatility smile.
IV Rank (7 DTE)
IV Rank (30 DTE)31.2MediumOct 26
Straddle Price (30 DTE)$4.55Oct 26
Beta Analysis
Risk Metrics
Beta: 1.6250
Alpha: 72.86%
Correlation: 0.2572
R-Squared: 6.6%
Stock Volatility: 80.5%
Market Volatility: 12.7%
Analysis Details
Benchmark: SPY
Data Points: 251
Period: 252 trading days
Data Points: 251
Period: 252 trading days
Interpretation:
High volatility - stock moves more than market
High volatility - stock moves more than market
Beta & Alpha Over Time
Notable investors who own CGEM
5 of 37 tracked investors
| Investor | Value | Share of their portfolio | Rank | Q/Q shares | Source |
|---|---|---|---|---|---|
| Citadel Hedge fund Ken Griffin | $7.2M | #1817 of 6285 | +57.2% | 13F | |
| Millennium Management Hedge fund Izzy Englander | $6.3M | #1908 of 3716 | -0.1% | 13F | |
| Renaissance Technologies Hedge fund Jim Simons | $6.0M | #1363 of 3138 | +0.8% | 13F | |
| Point72 Hedge fund Steve Cohen | $1.4M | #1391 of 1945 | -91.7% | 13F | |
| Rockefeller Capital Management Family office Rockefeller family | $12K | #3943 of 4729 | 0.0% | 13F |
Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions
CGEM Institutional Ownership (13F)
Latest filings — 2026-09-30
? 13F Guide
Diluted shares outstanding: 60,020,000 (as of 2026-06-30)
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
5 filers$3.39M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Susquehanna International Group, LLP Custodian | $1.58M | 46.58% | 2026-06-30 |
| 2 | Citadel Advisors LLC Custodian | $919.61K | 27.17% | 2026-06-30 |
| 3 | Jane Street Group, LLC Custodian | $508.06K | 15.01% | 2026-06-30 |
| 4 | Millennium Management LLC Custodian | $364.20K | 10.76% | 2026-06-30 |
| 5 | Simplex Trading, LLC Custodian | $16.39K | 0.48% | 2026-06-30 |
5 filers$2.81M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Citadel Advisors LLC Custodian | $1.19M | 42.23% | 2026-06-30 |
| 2 | Jane Street Group, LLC Custodian | $668.31K | 23.77% | 2026-06-30 |
| 3 | Susquehanna International Group, LLP Custodian | $655.56K | 23.32% | 2026-06-30 |
| 4 | GROUP ONE TRADING LLC Custodian | $233.09K | 8.29% | 2026-06-30 |
| 5 | Simplex Trading, LLC Custodian | $67.38K | 2.40% | 2026-06-30 |
CGEM Insider Trading (Form 4)
Latest: 2026-09-10Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-09-10 | Jennifer Michaelson | Chief Scientific Officer | Mixed | −4,000 | $15.81 | -$155.4K | EDGAR |
| 2026-08-14 | Jennifer Michaelson | Chief Scientific Officer | Mixed | — | $12.28 | -$478.8K | EDGAR |
| 2026-07-07 | Jennifer Michaelson | Chief Scientific Officer | Mixed | −4,000 | $13.31 | -$125.4K | EDGAR |
| 2026-07-02 | Jacquelyn L Sumer | Chief Legal Officer | Award (A) | +2,470 | $8.60 | $21.2K | EDGAR |
| 2026-07-02 | Mary Kay Fenton | Chief Financial Officer | Award (A) | +1,541 | $8.60 | $13.3K | EDGAR |
| 2026-06-18 | Stephen W Webster | Director | Grant (A) | +25,319 opt | — | EDGAR | |
| 2026-06-18 | Mittie Doyle | Director | Grant (A) | +21,781 opt | — | EDGAR | |
| 2026-06-18 | Mary Thistle | Director | Grant (A) | +25,319 opt | — | EDGAR | |
| 2026-06-18 | David D. Meek | Director | Grant (A) | +25,319 opt | — | EDGAR | |
| 2026-06-18 | Anthony Rosenberg | Director | Grant (A) | +25,319 opt | — | EDGAR | |
| 2026-06-18 | Andrew R Allen | Director | Grant (A) | +21,781 opt | — | EDGAR | |
| 2026-05-06 | Jennifer Michaelson | Chief Scientific Officer | Mixed | −4,000 | $11.18 | -$99.8K | EDGAR |
| 2026-03-09 | Jennifer Michaelson | Chief Scientific Officer | Mixed | −4,000 | $11.89 | -$108.2K | EDGAR |
| 2026-02-26 | Jennifer Michaelson | Chief Scientific Officer | Sell (S) | −1,780 | $14.14 | -$25.2K | EDGAR |
| 2026-02-25 | Nadim Ahmed | President and CEO | Sell (S) | −13,515 | $14.47 | -$195.6K | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
CGEM Insider Holdings
7 insiders · @ $14.54
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Lynx1 Capital Management LP | 10%+ Owner | 8,963,500 | $130.33M | $26.65M | 3 | 2025-10-30 |
| 2 | Nadim Ahmed | President and CEO | 390,803 | $5.68M | -$693.9K | 18 | 2026-02-25 |
| 3 | Corrine Savill | Chief Business Officer | 240,990 | $3.50M | -$2.54M | 10 | 2026-02-19 |
| 4 | Jennifer Michaelson | Chief Scientific Officer | 166,844 | $2.43M | -$4.82M | 49 | 2026-09-10 |
| 5 | Jeffrey Alan Jones | Chief Medical Officer | 159,968 | $2.33M | -$309.6K | 16 | 2026-02-25 |
| 6 | Jacquelyn L Sumer | Chief Legal Officer | 130,559 | $1.90M | -$235.6K | 17 | 2026-07-02 |
| 7 | Mary Kay Fenton | Chief Financial Officer | 127,921 | $1.86M | -$59.9K | 6 | 2026-07-02 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
CGEM Board & Officers
As of SEC filings through Sep 10, 2026Directors 7
- Anthony Rosenberg · since Jan 7, 2021
- Stephen W Webster · since Jan 7, 2021
- Nadim Ahmed · since Oct 18, 2021
- David D. Meek · since May 15, 2024
- Mary Thistle · since Aug 8, 2024
- Andrew R Allen · since Aug 7, 2025
- Mittie Doyle · since Aug 7, 2025
Officers 6
- Nadim Ahmed · President and CEO · since Oct 18, 2021
- Mary Kay Fenton · Chief Financial Officer · since Apr 29, 2024
- Jeffrey Alan Jones · Chief Medical Officer · since Feb 28, 2022
- Jacquelyn L Sumer · Chief Legal Officer · since Aug 15, 2022
- Corrine Savill · Chief Business Officer · listed since Feb 2023
- Jennifer Michaelson · Chief Scientific Officer · listed since Dec 2023
10% owners 2
- Lynx1 Capital Management LP (entity) · since Oct 8, 2025
- Weston Nichols · since Oct 8, 2025
Changes in the last 10 years (61)
| Oct 8, 2025 | Weston Nichols became a 10% owner |
| Oct 8, 2025 | Lynx1 Capital Management LP became a 10% owner |
| Aug 7, 2025 | Mittie Doyle became a director |
| Aug 7, 2025 | Andrew R Allen became a director |
| Aug 4, 2025 | The company announced the departure of Anne-Marie Martin from the board in an SEC filing |
| Aug 8, 2024 | Mary Thistle became a director |
| May 15, 2024 | David D. Meek became a director |
| May 9, 2024 | The company announced the departure of Thomas Ebeling from the board in an SEC filing |
| Apr 29, 2024 | Mary Kay Fenton became Chief Financial Officer |
| Mar 29, 2024 | Nate Nguyen became Interim PAO and PFO |
| Dec 13, 2023 | Jennifer Michaelson listed as Chief Scientific Officer (previously Chief Development Officer) in SEC filings |
| Jun 8, 2023 | The company announced the departure of Patrick Baeuerle as Acting Chief Scientific Officer, Biologics in an SEC filing |
| Feb 21, 2023 | Corrine Savill listed as Chief Business Officer (previously Acting Chief Business Officer) in SEC filings |
| Jan 19, 2023 | Mark N Lampert reported in an SEC filing no longer being a 10% owner |
| Jan 19, 2023 | Bvf Partners L P/il reported in an SEC filing no longer being a 10% owner |
| Jan 19, 2023 | Bvf Inc/il reported in an SEC filing no longer being a 10% owner |
| Jan 19, 2023 | Bvf Gp Holdings LLC reported in an SEC filing no longer being a 10% owner |
| Nov 1, 2022 | The company announced the departure of David P. Ryan from the board in an SEC filing |
| Nov 1, 2022 | The company announced the departure of Ansbert Gadicke from the board in an SEC filing |
| Nov 1, 2022 | David P. Ryan became a director |
| Aug 15, 2022 | Jacquelyn L Sumer became Chief Legal Officer |
| Aug 4, 2022 | Vision SCS F2 reported in an SEC filing no longer being a 10% owner |
| Aug 4, 2022 | Morana Jovan-Embiricos reported in an SEC filing no longer being a 10% owner |
| Mar 1, 2022 | Anne-Marie Martin became a director |
| Feb 28, 2022 | Jeffrey Alan Jones became Chief Medical Officer |
| Feb 15, 2022 | Jennifer Michaelson listed as Chief Development Officer (previously Chief Development Officer, Biologics) in SEC filings |
| Dec 31, 2021 | Mark N Lampert became a 10% owner |
| Dec 31, 2021 | Bvf Partners L P/il became a 10% owner |
| Dec 31, 2021 | Bvf Inc/il became a 10% owner |
| Dec 31, 2021 | Bvf Gp Holdings LLC became a 10% owner |
| Dec 27, 2021 | The company announced the departure of Morana Jovan-Embiricos from the board in an SEC filing |
| Oct 18, 2021 | Nadim Ahmed became a director |
| Oct 18, 2021 | Nadim Ahmed became President and CEO |
| Jan 14, 2021 | F2 GC, LLC first on file as a 10% owner |
| Jan 7, 2021 | Vision SCS F2 became a 10% owner |
| Jan 7, 2021 | UBS Oncology Impact Fund L.P. became a 10% owner |
| Jan 7, 2021 | Thomas Ebeling became a director |
| Jan 7, 2021 | Stephen W Webster became a director |
| Jan 7, 2021 | Raymond T Keane became Chief Legal Officer |
| Jan 7, 2021 | Patrick Baeuerle became Acting Chief Scientific Officer, Biologics |
| Jan 7, 2021 | Owen Hughes became a director |
| Jan 7, 2021 | Owen Hughes became President and CEO |
| Jan 7, 2021 | Oncology Impact Fund (Cayman) Management L.P. became a 10% owner |
| Jan 7, 2021 | Morana Jovan-Embiricos became a director |
| Jan 7, 2021 | Morana Jovan-Embiricos became a 10% owner |
| Jan 7, 2021 | MPM Oncology Impact Management GP LLC became a 10% owner |
| Jan 7, 2021 | Leigh Zawel became Chief Scientific Officer, Small Molecules |
| Jan 7, 2021 | Jon Marc Wigginton became Chief Medical Officer |
| Jan 7, 2021 | Jennifer Michaelson became Chief Development Officer, Biologics |
| Jan 7, 2021 | Jeffrey Trigilio became Chief Financial Officer |
| Jan 7, 2021 | Globeways Holdings Ltd became a 10% owner |
| Jan 7, 2021 | F2 Mc, LLC became a 10% owner |
| Jan 7, 2021 | F2 MG Ltd became a 10% owner |
| Jan 7, 2021 | F2 Bioscience I 2017 Ltd became a 10% owner |
| Jan 7, 2021 | F2 Bio TD, LLC became a 10% owner |
| Jan 7, 2021 | F2 - TPO Investments LLC became a 10% owner |
| Jan 7, 2021 | Corrine Savill became Acting Chief Business Officer |
| Jan 7, 2021 | BioImpact Capital LLC became a 10% owner |
| Jan 7, 2021 | Anthony Rosenberg became a director |
| Jan 7, 2021 | Ansbert Gadicke became a director |
| Jan 7, 2021 | Ansbert Gadicke became a 10% owner |
Not reported recently (18)
- Nate Nguyen · Last reported as Interim PAO and PFO in an SEC filing dated Apr 2, 2024
- Jeffrey Trigilio · Last reported as Chief Financial Officer in an SEC filing dated Feb 23, 2024
- Ansbert Gadicke · Last reported as a 10% owner in an SEC filing dated Feb 10, 2023
- F2 Bioscience I 2017 Ltd · Last reported as a 10% owner in an SEC filing dated Jun 23, 2022
- Leigh Zawel · Last reported as Chief Scientific Officer, Small Molecules in an SEC filing dated Feb 15, 2022
- Raymond T Keane · Last reported as Chief Legal Officer in an SEC filing dated Feb 15, 2022
- UBS Oncology Impact Fund L.P. · Last reported as a 10% owner in an SEC filing dated Sep 20, 2021
- BioImpact Capital LLC · Last reported as a 10% owner in an SEC filing dated Sep 20, 2021
- Oncology Impact Fund (Cayman) Management L.P. · Last reported as a 10% owner in an SEC filing dated Sep 20, 2021
- MPM Oncology Impact Management GP LLC · Last reported as a 10% owner in an SEC filing dated Aug 25, 2021
- F2 MG Ltd · Last reported as a 10% owner in an SEC filing dated Jan 14, 2021
- F2 - TPO Investments LLC · Last reported as a 10% owner in an SEC filing dated Jan 14, 2021
- F2 Mc, LLC · Last reported as a 10% owner in an SEC filing dated Jan 14, 2021
- Globeways Holdings Ltd · Last reported as a 10% owner in an SEC filing dated Jan 14, 2021
- Owen Hughes · Last reported as a director in an SEC filing dated Jan 14, 2021
- F2 Bio TD, LLC · Last reported as a 10% owner in an SEC filing dated Jan 14, 2021
- F2 GC, LLC · Last reported as a 10% owner in an SEC filing dated Jan 14, 2021
- Jon Marc Wigginton · Last reported as Chief Medical Officer in an SEC filing dated Jan 11, 2021
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
CGEM Proposed Insider Sales (Form 144)
Latest: 2026-09-08
? Form 144 Guide
Last 30d:
0 filings
· Last 90d:
2 filings
· $765K notice value
· 1 unique filer
· 100% under 10b5-1 plans
What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.
How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.
10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.
"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.
Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.
Top 90-day filers:
JENNIFER MICHAELSON (2, $765K)
| Filed | Filer | Role | Shares | Notice Value | Planned Sale | Broker | Plan | Link |
|---|---|---|---|---|---|---|---|---|
| 2026-09-08 | JENNIFER MICHAELSON | Officer | 8,000 | $176.7K | 2026-09-08 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-08-13 | JENNIFER MICHAELSON | Officer | 30,000 | $588.0K | 2026-08-13 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-07-06 | JENNIFER MICHAELSON | Officer | 8,000 | $141.0K | 2026-07-06 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-05-05 | JENNIFER MICHAELSON | Officer | 8,000 | $122.7K | 2026-05-05 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-03-05 | JENNIFER MICHAELSON | Officer | 8,000 | $130.4K | 2026-03-05 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-02-25 | JENNIFER MICHAELSON | Officer | 1,780 | $25.4K | 2026-02-25 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-02-23 | JENNIFER MICHAELSON | Officer | 1,752 | $23.9K | 2026-02-23 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-02-20 | JENNIFER MICHAELSON | Officer | 8,000 | $111.0K | 2026-02-20 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-01-22 | JENNIFER MICHAELSON | Officer | 4,000 | $46.4K | 2026-01-22 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2025-12-19 | JENNIFER MICHAELSON | Officer | 1,345 | $13.4K | 2025-12-19 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
ETF Holders
61 ETFs hold CGEM
25 shown · $139.15M total exposure · 0.03% AUM-weighted avg weight
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|---|---|---|---|---|---|
| 1 | VTI Vanguard Morningstar Total Stock Market ETF | Vanguard | 0.00% | $30.0M | — | 2026-09-30 |
| 2 | IWM iShares Russell 2000 ETF | iShares (BlackRock) | 0.03% | $21.9M | $74.6B | 2026-10-23 |
| 3 | XBI State Street® SPDR® S&P® Biotech ETF | SPDR (State Street) | 0.18% | $18.7M | $10.4B | 2026-10-23 |
| 4 | VXF Vanguard Extended Market ETF | Vanguard | 0.01% | $9.6M | — | 2026-09-30 |
| 5 | IWN iShares Russell 2000 Value ETF | iShares (BlackRock) | 0.06% | $8.1M | $13.9B | 2026-10-23 |
| 6 | VTWO Vanguard Russell 2000 ETF | Vanguard | 0.03% | $5.4M | — | 2026-09-30 |
| 7 | IBB iShares Biotechnology ETF | iShares (BlackRock) | 0.05% | $5.1M | $10.7B | 2026-10-23 |
| 8 | DFAS Dimensional US Small Cap ETF | Dimensional | 0.01% | $4.9M | — | 2026-10-23 |
| 9 | FESM Fidelity Enhanced Small Cap Core ETF | Fidelity | 0.07% | $4.5M | $6.6B | 2026-10-23 |
| 10 | SCHA Schwab U.S. Small-Cap ETF | Nport | 0.02% | $4.0M | — | 2026-05-31 |
| 11 | DFAC Dimensional US Core Equity 2 ETF | Dimensional | 0.00% | $3.5M | — | 2026-10-23 |
| 12 | DFMC Dimensional US Micro Cap ETF | Dimensional | 0.04% | $2.9M | — | 2026-10-23 |
| 13 | TMSL T. Rowe Price Small-Mid Cap ETF | Nport | 0.11% | $2.8M | — | 2026-06-30 |
| 14 | IWC iShares Micro-Cap ETF | iShares (BlackRock) | 0.22% | $2.7M | $1.2B | 2026-10-23 |
| 15 | AVSC Avantis U.S. Small Cap Equity ETF | Avantis | 0.06% | $2.0M | $3.2B | 2026-10-23 |
| 16 | VHT Vanguard Health Care ETF | Vanguard | 0.01% | $1.8M | — | 2026-09-30 |
| 17 | SMLF iShares U.S. Small-Cap Equity Factor ETF | iShares (BlackRock) | 0.04% | $1.7M | $4.2B | 2026-10-23 |
| 18 | DWAS Invesco Dorsey Wright SmallCap Momentum ETF | Nport | 0.41% | $1.7M | — | 2026-05-31 |
| 19 | VFMO Vanguard U.S. Momentum Factor ETF | Vanguard | 0.09% | $1.6M | — | 2026-10-23 |
| 20 | PRFZ Invesco RAFI US 1500 Small-Mid ETF | Nport | 0.06% | $1.5M | — | 2026-07-31 |
| 21 | ITOT iShares Core S&P Total U.S. Stock Market ETF | iShares (BlackRock) | 0.00% | $1.0M | $96.5B | 2026-10-23 |
| 22 | CANC Tema Oncology ETF | Nport | 0.59% | $1.0M | — | 2026-05-31 |
| 23 | DCOR Dimensional US Core Equity 1 ETF | Dimensional | 0.00% | $856,596 | — | 2026-10-23 |
| 24 | VTWV Vanguard Russell 2000 Value ETF | Vanguard | 0.06% | $855,885 | — | 2026-09-30 |
| 25 | LABU Direxion Daily S&P Biotech Bull 3X ETF | Direxion | 0.13% | $728,961 | — | 2026-10-26 |
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
Trailing P/E
—
TTM Diluted EPS
$-2.97
TTM Revenue
—
TTM Net Income
$-178.84M
TTM Op. Cash Flow
$-159.25M
Quarterly figures (12 quarters)
| Quarter | Period End | Revenue | Net Income | Diluted EPS | Op. Cash Flow |
|---|---|---|---|---|---|
| Q2 '26 | 2026-06-30 | — | $-53.70M | $-0.87 | $-38.22M |
| Q1 '26 | 2026-03-31 | — | $-45.48M | $-0.75 | $-46.05M |
| Q4 '25 | 2025-12-31 | — | $-29.05M | $-0.49 | $-38.11M |
| Q3 '25 | 2025-09-30 | — | $-50.61M | $-0.86 | $-36.88M |
| Q2 '25 | 2025-06-30 | — | $-70.06M | $-1.19 | $-57.61M |
| Q1 '25 | 2025-03-31 | — | $-43.70M | $-0.74 | $-43.16M |
| Q4 '24 | 2024-12-31 | — | $-29.66M | $-0.48 | $-36.63M |
| Q3 '24 | 2024-09-30 | — | $-40.56M | $-0.69 | $-34.14M |
| Q2 '24 | 2024-06-30 | — | $-42.03M | $-0.75 | $-36.29M |
| Q1 '24 | 2024-03-31 | — | $-32.29M | $-0.75 | $-38.25M |
| Q4 '23 | 2023-12-31 | — | $-4.09M | $-0.06 | $-18.13M |
| Q3 '23 | 2023-09-30 | — | $-39.18M | $-0.91 | $-34.14M |
Q2 2026 • period ending 2026-06-30 • filed 2026-08-06
Valuation
Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.
Price Multiples
- P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
- P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
- P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
- EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
- EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
- ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
- ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
- Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
- FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
- Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
- Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
- Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
- Multiples expanding while earnings are flat = sentiment-driven rally.
- Multiples compressing while earnings grow = value coming from fundamentals.
P/E
—
P/B
2.71
P/S
—
EV/EBITDA
—
EV/Sales
—
ROE
-55.6%
ROA
-49.2%
Div Yield
0.00%
FCF Yield
-18.25%
Debt/Equity
0.00
Current Ratio
—
Market Cap
$872.69M
as of 2026-10-26
Short Interest & Float
Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.
Metric definitions
- Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
- SI % of Float — short interest / free float. The key crowding metric.
- Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
- Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
- Free Float — shares available for public trading (total shares minus insider / restricted).
- Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
- SI % of Float < 5% — typical, no particular signal.
- 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
- 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
- >30% — extreme; borrow is likely expensive and squeeze risk is material.
- Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
- Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
- A sudden drop in SI after a rally may indicate a squeeze in progress.
Short interest is reported mid-month and end-of-month; short volume is daily.
Short Interest
7.63M
SI % of Float
14.26%
Days to Cover
5.07
Short Vol Ratio
72.1%
Free Float
53.54M
Float %
83.2%
Short interest 2026-09-30 • Short volume 2026-10-26 • Float 2026-08-14